idenix pharmaceuticals inc

This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today. 52-Week High:

• Idenix Pharmaceuticals Inc.
  
  (Nasdaq: IDIX) high of $14.59. Idenix is up 100-percent-plus for the week, following the proposed buyout of Inhibitex, Inc.
  
  (Nasdaq: INHX) by Bristol-Myers Squibb (NYSE: BMY). As previously mentioned, with Inhibitex gone, Idenix becomes the number one takeover target in the HCV sector.
  
  Notably, Idenix has added over $700 million to its market cap this week alone.

This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today. 52-Week High:

• Gilead Sciences Inc.
  
  (Nasdaq: GILD) high of $45.04. Could be seeing continued upside from the acquisition of Inhibitex (Nasdaq: INHX) by Bristol-Myers Squibb, as Gilead agreed to acquire Pharmasset (Nasdaq: VRUS) earlier in the year.
  
  Shares moved as much as 5.4 percent higher on the session.
• Idenix Pharmaceuticals Inc. (Nasdaq: IDIX) high of $11.72.

This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today. 52-Week High:

• Idenix Pharmaceuticals, Inc.
  
  (Nasdaq: IDIX) high of $10.39. Idenix up about 47 percent to its new 52-week high Monday, following the announced acquisition of Inhibitex (Nasdaq: INHX) by Bristol-Myers Squibb over the weekend, as well as the Phase I initiation of NSSA inhibitor IDX719.
• Apple Inc.
  
  (Nasdaq: AAPL) high of $427.75.

Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) 25% LOWER; announced that its '761 has been placed on a clinical hold by the FDA. Click here to see the full update from Idenix.

TriQuint Semiconductor, Inc. (NASDAQ: TQNT) 13.8% LOWER; reported Q4 EPS of $0.25, $0.03 worse than the analyst estimate of $0.28.

Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) 47.9% LOWER; receives notice from the U.S. FDA that a clinical hold has been placed on IDX184 and IDX320 programs.

A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation.

China Sky One Medical, Inc. (Nasdaq: CSKI) 30.3% LOWER; Friday after the close, lowered its FY10 revenue guidance from a prior range of $160-$164 million to between $128 million and $136 million.

Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) 45.6% LOWER; receives notice from the U.S. FDA that a clinical hold has been placed on IDX184 and IDX320 programs.

A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation.

Spherix (Nasdaq: SPEX) 32% LOWER; looks like technicians are getting active on the stock today as shares gapped below the always-important 200-day smooth moving average.

Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) 20% LOWER; reports a Q3 loss of $0.18, 6 cents better than the analyst estimate of ($0.24).

Revenue for the quarter was $3.1 million, which compares to the estimate of $3.04 million. The company expects that its current cash, cash equivalents and marketable securities can fund operations through at least the next twelve months.

AXT Inc (NASDAQ: AXTI) 19% HIGHER; reports Q3 EPS of $0.07, 9 cents better than the analyst estimate of ($0.02).

JDA Software (Nasdaq: JDAS) 22.8% HIGHER; reports Q2 EPS of $0.47, 17 cents better than the analyst estimate of $0.30.

Revenue for the quarter was $99.5 million, versus the consensus of $86.2 million. Idenix Pharmaceuticals, Inc.

(Nasdaq: IDIX) 22% LOWER; reports Q2 loss of $0.28, 3 cents below than the analyst estimate of ($0.25). Revenue for the quarter was $2.45 million, versus the consensus of $3.39 million.

U.S. Physical Therapy, Inc. (NASDAQ: USPH) 15% HIGHER; reports preliminary Q2 EPS of $0.31 vs.